PURPOSE: Aggressive inpatient chemoimmunotherapy protocols for @entity320 have yielded encouraging response rates but have required lengthy hospitalizations. To reduce or eliminate the need for hospitalization, we have developed an outpatient chemoimmunotherapy regimen and assessed its efficacy and @entity137 in 53 @entity1 treated at the University of Washington Medical Center. @entity1 AND METHODS: Eligible @entity1 with measurable @entity320 received carmustine (150 mg/m2 every 6-8 weeks) and @entity2699 (660 mg/m2) and @entity900 (75 mg/m2) every 3 to 4 weeks in an infusion center plus @entity440 (20 mg/day). @entity1 self-administered subcutaneous recombinant @entity1199 ( @entity5041 ) at 3 MIU/m2/day on days 3 to 9, and recombinant interferon alfa-2a (rIFN-alpha 2a) at 3 MIU on day 3 and at 5 MIU/m2/day on days 5, 7, and 9. Maintenance rIFN-alpha 2a was self-administered subcutaneously at 5 MIU/m2 tiw for 12 months after complete or stable partial response. Response and survival were assessed. RESULTS: Fifty-three @entity1 (median age = 49 years) have received 181 cycles. To date, there have been 10 complete responses (19%) lasting 2 to 28+ months and 12 partial responses (23%) lasting 2 to 11 months, for an overall response rate of 42% (95% confidence interval, 28%-55%). The median overall survival was 12 months. Grade 3/4 @entity391 occurred in 32% of cycles, but hospitalization for supplemental intravenous fluids was required in only 11% of cycles for a median of 3 days. Grade 4 @entity882 and @entity1398 occurred in 9% and 8% of cycles, respectively. Grade 3 @entity8 occurred in only one cycle and was reversible. CONCLUSION: A chemoimmunotherapy regimen for @entity1 with @entity320 has been defined that is well tolerated on an outpatient basis and is associated with a median survival comparable to that with @entity146 inpatient chemoimmunotherapy regimens.

Updated analysis of an outpatient chemoimmunotherapy regimen for treating XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity2699 :: ('MESH:D003606', 'Chemical') :: ['dacarbazine'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity5041 :: ('116562(Tax:10116)', 'Gene') :: ['rIL-2'] @entity1199 :: ('3558', 'Gene') :: ['interleukin-2'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']
